Vincrystine is named as an intervention in 15 current clinical trials in our Canada, Israel, Australia, Mexico, China, Germany, France, Spain, Belgium, Switzerland, Austria, Portugal and Brazil registers. 8 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Children's Oncology Group (8). The most-studied condition is Acute Lymphoblastic Leukemia.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Acute Lymphoblastic Leukemia | 2 |
| B-cell Non-Hodgkin Lymphoma | 1 |
| Diffuse Large B-cell Lymphoma | 1 |
| Follicular Lymphoma | 1 |
| Acute Lymphoid Leukemia | 1 |
| Minimal Residual Disease | 1 |
| Gene Abnormality | 1 |
| Chemotherapeutic Toxicity | 1 |
| Childhood Medulloblastoma | 1 |
| Pleuropulmonary Blastoma | 1 |
| Hematopoietic and Lymphoid Cell Neoplasm | 1 |
| Malignant Solid Neoplasm | 1 |
| Embryonal Rhabdomyosarcoma | 1 |
| Fusion-Negative Alveolar Rhabdomyosarcoma | 1 |
| Spindle Cell/Sclerosing Rhabdomyosarcoma | 1 |
| Bilateral Retinoblastoma | 1 |
| Childhood Intraocular Retinoblastoma | 1 |
| Group D Retinoblastoma | 1 |
| Stage I Retinoblastoma | 1 |
| Medulloblastoma | 1 |
| Anaplastic Kidney Wilms Tumor | 1 |
| Recurrent Kidney Wilms Tumor | 1 |
| Stage II Kidney Wilms Tumor | 1 |
| Stage III Kidney Wilms Tumor | 1 |
| Stage I Mixed Cell Type Kidney Wilms Tumor | 1 |
| Stage II Mixed Cell Type Kidney Wilms Tumor | 1 |
| Stage III Mixed Cell Type Kidney Wilms Tumor | 1 |
| Stage IV Mixed Cell Type Kidney Wilms Tumor | 1 |
| B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 1 |
| Metastatic Ewing Sarcoma | 1 |
| Metastatic Malignant Neoplasm in the Bone | 1 |
| Metastatic Malignant Neoplasm in the Bone Marrow | 1 |
| Metastatic Malignant Neoplasm in the Lung | 1 |
| B Acute Lymphoblastic Leukemia | 1 |
| B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | 1 |
| Recurrent Acute Lymphoblastic Leukemia | 1 |
A trial with sites in more than one country appears in each of those registers.
15 current trials in our Canada, Israel, Australia, Mexico, China, Germany, France, Spain, Belgium, Switzerland, Austria, Portugal and Brazil registers name Vincrystine as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 8 of the 15 trials are recruiting: 6 with sites in Canada, 4 with sites in Israel, 4 with sites in Australia, 2 with sites in Mexico, 1 with sites in China and 1 with sites in Brazil. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Children's Oncology Group (8), National Cancer Institute (NCI) (3), Guangzhou Lupeng Pharmaceutical Company LTD (1) and Institute of Hematology & Blood Diseases Hospital, China (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Vincrystine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Vincrystine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Vincrystine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.